The coming of age of the angiotensin hypothesis in Alzheimer's disease: Progress toward disease prevention and treatment?

Patrick Gavin Kehoe*

*Corresponding author for this work

Research output: Contribution to journalReview article (Academic Journal)peer-review

47 Citations (Scopus)
245 Downloads (Pure)

Abstract

There is wide recognition of a complex association between midlife hypertension and cardiovascular disease and later development of Alzheimer's disease (AD) and cognitive impairment. While significant progress has been made in reducing rates of mortality and morbidity due to cardiovascular disease over the last thirty years, progress towards effective treatments for AD has been slower. Despite the known association between hypertension and dementia, research into each disease has largely been undertaken in parallel and independently. Yet over the last decade and a half, the emergence of converging findings from pre-clinical and clinical research has shown how the renin angiotensin system (RAS), which is very important in blood pressure regulation and cardiovascular disease, warrants careful consideration in the pathogenesis of AD. Numerous components of the RAS have now been found to be altered in AD such that the multifunctional and potent vasoconstrictor angiotensin II, and similarly acting angiotensin III, are greatly altered at the expense of other RAS signaling peptides considered to contribute to neuronal and cognitive function. Collectively these changes may contribute to many of the neuropathological hallmarks of AD, as well as observed progressive deficiencies in cognitive function, while also linking elements of a number of the proposed hypotheses for the cause of AD. This review discusses the emergence of the RAS and its likely importance in AD, not only because of the multiple facets of its involvement, but also perhaps fortuitously because of the ready availability of numerous RAS-acting drugs, that could be repurposed as interventions in AD.

Original languageEnglish
Pages (from-to)1443-1466
Number of pages24
JournalJournal of Alzheimer's Disease
Volume62
Issue number3
Early online date13 Mar 2018
DOIs
Publication statusPublished - Mar 2018

Keywords

  • ACE
  • Acetylcholine
  • Alzheimer's disease
  • Amyloid-β
  • Angiotensin
  • Cognitive decline
  • Dementia
  • Drug repurposing
  • Epidemiology
  • Hypertension
  • Treatment
  • Vascular

Fingerprint

Dive into the research topics of 'The coming of age of the angiotensin hypothesis in Alzheimer's disease: Progress toward disease prevention and treatment?'. Together they form a unique fingerprint.

Cite this